The Importance of Comparative Analysis of Targeted Novel Therapies and Relapse Refractory CLL

I was looking at your CV and I saw a paper you did, 2021, it was actually somehow a letter to the editor. Comparative analysis of targeted novel therapies and relapse refractory CLL. And if I understand this correctly in terms of how you looked at it, it suggests you saw greater efficacy with Venetoclax and BGK. Did I read that correctly?Yeah, I mean, we have seen as it's a great drug to salvage BTK failures. I think this is much better than what we've seen in terms of going to a PI3 kinase inhibitor or something along those lines. It hasn't shown any efficacy differences in terms of inferiority and or